Drug Profile
HMPL 002
Alternative Names: HMPL-002Latest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator Hutchison MediPharma
- Developer HUTCHMED
- Class Antineoplastics; Chemosensitisers; Radiation-sensitising agents; Radiosensitisers
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Head and neck cancer
- Suspended Non-small cell lung cancer
Most Recent Events
- 09 Jun 2021 Hutchison MediPharma has been acquired and merged into HUTCHMED
- 04 Feb 2009 Suspended - Phase-I for Head and neck cancer in USA (PO)
- 04 Feb 2009 Suspended - Phase-II for Non-small cell lung cancer in China (PO)